Clairvoyant Therapeutics
VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.
"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.
"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."
Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.
Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov
-30-
For more information:
Damian Kettlewell
damian@clairvoyantrx.com
SOURCE: Clairvoyant Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom